Neuros Medical

# Neuros Medical: High-Level Overview

Neuros Medical is a medical device company developing neuromodulation therapies for chronic pain management, specifically targeting conditions where traditional treatments have failed.[1][4] Founded in 2008 and headquartered in Willoughby Hills, Ohio, the company has developed the Altius® Direct Electrical Nerve Stimulation System, which received FDA approval for treating chronic post-amputation pain in lower limb amputees.[4][7]

The company addresses a significant unmet medical need: chronic pain in amputees who have exhausted conventional therapies and face potential opioid dependency.[4] Neuros Medical's core innovation uses high-frequency electrical stimulation delivered directly to peripheral nerves to block pain signals before they reach the brain, offering patients on-demand, patient-controlled relief without the risks associated with opioid medications.[1][4] The company achieved a major commercial milestone in July 2025 with the first FDA-approved commercial implant of the Altius System, marking the beginning of its market entry.[4]

# Origin Story

Neuros Medical was founded in October 2008 with a mission to develop proprietary electrical stimulation therapies for chronic pain conditions.[2][3] The company's leadership brings deep expertise in both neuromodulation technology and healthcare commercialization. Jon Snyder, President and CEO, brings nearly 25 years of biomedical and healthcare experience from companies including Cyberonics, Cardinal Health, and Fortune 500 organizations.[2] Zi-Ping Fang, Chief Scientific Officer, holds a PhD in Biomedical Engineering focused on neuromodulation from Case Western Reserve University and has over 25 years of R&D experience in neuromodulation, including prior roles at Nevro and NeuroControl leading to FDA approvals.[2]

The company's patented Electrical Nerve Block (ENB) platform technology emerged from this deep technical expertise in neuromodulation. Rather than pursuing a broad pain management approach, Neuros Medical strategically focused its development efforts on specific high-impact indications, beginning with post-amputation pain—a condition affecting hundreds of thousands of lower limb amputees in the United States with limited effective treatment options.[4]

# Core Differentiators

• First-to-market FDA approval: The Altius System is the only FDA-approved device specifically designed for chronic post-amputation pain in lower limb amputees, providing a first-mover advantage in this indication.[4][7]

• Patented electrical nerve block technology: Neuros Medical's proprietary platform delivers high-frequency stimulation directly to peripheral nerves, offering a mechanistically distinct approach from other neuromodulation therapies.[1][3]

• Patient-controlled, on-demand design: Unlike many implantable devices requiring scheduled treatments, Altius enables patients to initiate pain relief with a button press, improving quality of life and treatment adherence.[4][7]

• Clinical efficacy with opioid reduction: Clinical trial data demonstrates 30% pain reduction within 30 minutes and 50% reduction within 120 minutes, with 81% of opioid-using patients decreasing or eliminating opioid use.[7]

• Experienced leadership team: The executive team combines deep neuromodulation R&D expertise (Fang's background at Nevro and NeuroControl) with healthcare commercialization and venture capital experience (Snyder's background at Cyberonics and venture firms).[2]

# Role in the Broader Tech Landscape

Neuros Medical operates within the broader neuromodulation and biotech ecosystem, riding several converging trends. The opioid crisis has created urgent demand for non-pharmacological pain management alternatives, making neuromodulation therapies increasingly attractive to patients, providers, and payers.[4] The company benefits from decades of FDA precedent in approving neuromodulation devices, reducing regulatory risk compared to entirely novel therapeutic modalities.

The timing is particularly favorable: lower limb amputation rates continue rising due to diabetes and vascular disease, while the veteran population—a significant portion of amputees—has strong healthcare access and advocacy for innovative treatments.[4] Neuros Medical's focus on peripheral nerve stimulation rather than spinal cord stimulation also positions it in a less crowded market segment, allowing for differentiation and potentially faster adoption.

The company's success validates the broader shift toward precision neuromodulation—targeting specific nerves and pain pathways rather than broad central nervous system interventions. This approach aligns with industry trends toward more targeted, mechanism-based therapies with fewer systemic side effects.

# Quick Take & Future Outlook

Neuros Medical stands at an inflection point. The July 2025 first commercial implant marks the transition from development to revenue generation, with the company now focused on scaling manufacturing, building clinical evidence, and expanding reimbursement coverage.[4] The immediate priority will be establishing market penetration among lower limb amputees through partnerships with prosthetics providers and veteran healthcare networks.

Looking forward, the company's platform technology has potential applications beyond post-amputation pain—including chronic post-surgical pain, occipital neuralgia, and trigeminal neuralgia—suggesting a pathway to expand indications and addressable market.[1][2] Success in these adjacent indications could position Neuros Medical as a meaningful player in the neuromodulation space, particularly if clinical data continues to demonstrate superior efficacy and opioid-sparing benefits.

The company's venture backing through JumpStart Ventures (Evergreen and NEXT Funds) and RiverVest indicates investor confidence in both the technology and market opportunity.[1][3] As the opioid crisis remains a public health priority and neuromodulation gains acceptance as a standard-of-care alternative, Neuros Medical's focused strategy on high-need patient populations positions it well for sustainable growth and potential acquisition interest from larger medical device companies seeking neuromodulation capabilities.